Mark Lambiris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Lambiris has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Aita Signorell
Swiss Tropical and Public Health Institute
10 shared publications - Manuel W. Hetzel
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
10 shared publications - Nina C. Brunner
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
10 shared publications - Christian Lengeler
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
9 shared publications - Tristan T. Lee
Division of Clinical Epidemiology, Department of Clinical Research University Hospital Basel Basel Switzerland
9 shared publications - Elizabeth Omoluabi
Akena Associates, Nigeria
8 shared publications
Latest Publications
- 6 October 2025
- Published by Oxford University Press (OUP) in Nutrition Reviews
Acute Undernutrition and Child Development in Low- and Middle-Income Countries: A Meta-analysis
Context: The association between linear growth faltering and child development outcomes is generally well recognized; however, the relationship between metrics of acute undernutrition and development has received less attention. Objectives: We aimed to quantify the association between metrics of acute undernutrition in childhood with development outcomes in low- and middle-income countries (LMICs). Methods: We conducted a systematic literature review of observational studies that assessed the association between metrics of acute undernutrition, including body mass index-for-age z score (BMIZ), midupper arm circumference (MUAC), weight-for-height/-length z score (WHZ/WLZ), wasting (WHZ/WLZ < −2), and severe acute malnutrition (SAM) among children under 5 years of age with cognitive, motor, language, and socioemotional development assessed to 19 years of age. We estimated the pooled correlation and standardized mean difference (SMD) for cross-sectional and longitudinal studies. Results: A total of 113 studies from 40 LMICs were identified. Metrics of acute undernutrition were associated with lower cognitive and motor development scores. In longitudinal studies that reported multivariable-adjusted estimates for the cognitive domain, SAM was associated with −1.06 SD lower scores (95% CI: −1.41, −0.72) compared with children without SAM. SAM was also associated with lower motor scores in longitudinal studies with unadjusted estimates (SMD: −0.42; 95% CI: −0.68, −0.15). In longitudinal studies with multivariable estimates, wasting was associated with lower motor scores (SMD: −0.30; 95% CI: −0.54, −0.06), but there was no association with language (SMD: −0.08; 95% CI: −0.24, 0.07) or prosocial development scores (SMD: −0.18; 95% CI: −0.38, 0.02). Conclusion: Metrics of acute undernutrition in childhood were consistently associated with lower development scores, and the magnitude appeared stronger for children with SAM or wasting. Systematic Review Registration: PROSPERO registration no. CRD42022310077.
- 6 October 2025
- Published by Oxford University Press (OUP) in Nutrition Reviews
Acute Undernutrition and Child Development in Low- and Middle-Income Countries: A Meta-analysis
Context: The association between linear growth faltering and child development outcomes is generally well recognized; however, the relationship between metrics of acute undernutrition and development has received less attention. Objectives: We aimed to quantify the association between metrics of acute undernutrition in childhood with development outcomes in low- and middle-income countries (LMICs). Methods: We conducted a systematic literature review of observational studies that assessed the association between metrics of acute undernutrition, including body mass index-for-age z score (BMIZ), midupper arm circumference (MUAC), weight-for-height/-length z score (WHZ/WLZ), wasting (WHZ/WLZ < −2), and severe acute malnutrition (SAM) among children under 5 years of age with cognitive, motor, language, and socioemotional development assessed to 19 years of age. We estimated the pooled correlation and standardized mean difference (SMD) for cross-sectional and longitudinal studies. Results: A total of 113 studies from 40 LMICs were identified. Metrics of acute undernutrition were associated with lower cognitive and motor development scores. In longitudinal studies that reported multivariable-adjusted estimates for the cognitive domain, SAM was associated with −1.06 SD lower scores (95% CI: −1.41, −0.72) compared with children without SAM. SAM was also associated with lower motor scores in longitudinal studies with unadjusted estimates (SMD: −0.42; 95% CI: −0.68, −0.15). In longitudinal studies with multivariable estimates, wasting was associated with lower motor scores (SMD: −0.30; 95% CI: −0.54, −0.06), but there was no association with language (SMD: −0.08; 95% CI: −0.24, 0.07) or prosocial development scores (SMD: −0.18; 95% CI: −0.38, 0.02). Conclusion: Metrics of acute undernutrition in childhood were consistently associated with lower development scores, and the magnitude appeared stronger for children with SAM or wasting. Systematic Review Registration: PROSPERO registration no. CRD42022310077.
- Open Access
- 10 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0327814
Contributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data
Background: The concept of Value-Based Health Care (VBHC) seeks to maximise patient value by optimising health outcomes considering costs. However, necessary data are not readily available. In Switzerland, hospital accounting is disconnected from patient outcomes and treatment data. We demonstrate the feasibility of merging routine hospital data, including patient-reported outcome measures (PROMs), to implement core elements of VBHC in a real-world lung cancer centre. Methods: We developed a merging approach using records from 208 newly diagnosed lung cancer patients treated at University Hospital Basel between June 2020 and November 2023. Maximum patient follow-up was 12-months. Clinician-reported outcome measure (CROM) and PROM data collection followed the International Consortium for Health Outcomes Measurement (Lung Cancer Set) standard. Cost data were extracted from Switzerland’s standard hospital accounting system (REKOLE®). To illustrate analytical options offered by the merged data, we analysed partial correlations between costs and utility changes from baseline. Results: The merging approach successfully allocated costs to specific lung cancer treatments and separated costs for comorbidity care, enabling an initial presentation of cost distributions for different elements of care. Median total first-year hospital costs per lung cancer patient were CHF 77,834 (mean CHF 93,621). Immunotherapy incurred the highest median costs of CHF 45,394 (mean CHF 49,518), followed by surgery of CHF 41,665 (mean CHF 48,940). First-year costs for patients diagnosed with stage I tended to be lower than for later stages. A standard graphical tool was developed to track individual patient treatment, outcome, and cost over time. Conclusions: This proof-of-concept analysis demonstrates the feasibility of a novel data merging approach as a foundation for VBHC implementation. While limited by sample size and follow-up duration, our method supports future treatment-cost-benefit models. It is reproducible and scalable across other conditions and hospitals, enabling the development of lung cancer treatments towards greater value and efficiency.
- 10 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0327814
Open AccessContributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data
Background: The concept of Value-Based Health Care (VBHC) seeks to maximise patient value by optimising health outcomes considering costs. However, necessary data are not readily available. In Switzerland, hospital accounting is disconnected from patient outcomes and treatment data. We demonstrate the feasibility of merging routine hospital data, including patient-reported outcome measures (PROMs), to implement core elements of VBHC in a real-world lung cancer centre. Methods: We developed a merging approach using records from 208 newly diagnosed lung cancer patients treated at University Hospital Basel between June 2020 and November 2023. Maximum patient follow-up was 12-months. Clinician-reported outcome measure (CROM) and PROM data collection followed the International Consortium for Health Outcomes Measurement (Lung Cancer Set) standard. Cost data were extracted from Switzerland’s standard hospital accounting system (REKOLE®). To illustrate analytical options offered by the merged data, we analysed partial correlations between costs and utility changes from baseline. Results: The merging approach successfully allocated costs to specific lung cancer treatments and separated costs for comorbidity care, enabling an initial presentation of cost distributions for different elements of care. Median total first-year hospital costs per lung cancer patient were CHF 77,834 (mean CHF 93,621). Immunotherapy incurred the highest median costs of CHF 45,394 (mean CHF 49,518), followed by surgery of CHF 41,665 (mean CHF 48,940). First-year costs for patients diagnosed with stage I tended to be lower than for later stages. A standard graphical tool was developed to track individual patient treatment, outcome, and cost over time. Conclusions: This proof-of-concept analysis demonstrates the feasibility of a novel data merging approach as a foundation for VBHC implementation. While limited by sample size and follow-up duration, our method supports future treatment-cost-benefit models. It is reproducible and scalable across other conditions and hospitals, enabling the development of lung cancer treatments towards greater value and efficiency.
- Open Access
- 16 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004388
Human capital and lifetime income gains of scaling-up small-quantity lipid nutrient supplements among children under 2 years: A modelling analysis
Undernutrition in early childhood is associated with adverse health and developmental outcomes later in life and remains a persistent global public health problem. Providing small-quantity lipid nutrient supplements (SQ-LNS) to children aged 6-24 months improves child growth and neurodevelopmental outcomes, but the potential long-term benefits to human capital have not been previously estimated. We estimated the potential returns to schooling and lifetime income attributable to increasing coverage of SQ-LNS for children de novo meta-analysis of observational economic studies. Gains in school years attributable to scaling-up SQ-LNS to 90% coverage ranged from 0.14 million school years (95% uncertainty interval [UI]: 0.064, 0.25) in Burkina Faso to 1.18 million school years (95%UI: 0.54, 2.11) in Pakistan per five-year birth cohort. With an effect size of 18% return in income per one standard deviation increase in development, the estimated gains in lifetime income ranged from $US 0.41 billion (95% UI: 0.20, 0.68) in Burkina Faso to $US 6.91 billion (95% UI: 3.32, 11.4) in Pakistan per five-year birth cohort. Returns in income per child were above the estimated per child cost of providing SQ-LNS. These findings demonstrate that scaling-up SQ-LNS among children aged 6-24 months may lead to substantial human capital gains in countries with a high-burden of child undernutrition. Longitudinal studies on the long-term effects of SQ-LNS are needed to refine model parameters and to better characterize the impacts on broader health and human capital outcomes.
- 16 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004388
Open AccessHuman capital and lifetime income gains of scaling-up small-quantity lipid nutrient supplements among children under 2 years: A modelling analysis
Undernutrition in early childhood is associated with adverse health and developmental outcomes later in life and remains a persistent global public health problem. Providing small-quantity lipid nutrient supplements (SQ-LNS) to children aged 6-24 months improves child growth and neurodevelopmental outcomes, but the potential long-term benefits to human capital have not been previously estimated. We estimated the potential returns to schooling and lifetime income attributable to increasing coverage of SQ-LNS for children de novo meta-analysis of observational economic studies. Gains in school years attributable to scaling-up SQ-LNS to 90% coverage ranged from 0.14 million school years (95% uncertainty interval [UI]: 0.064, 0.25) in Burkina Faso to 1.18 million school years (95%UI: 0.54, 2.11) in Pakistan per five-year birth cohort. With an effect size of 18% return in income per one standard deviation increase in development, the estimated gains in lifetime income ranged from $US 0.41 billion (95% UI: 0.20, 0.68) in Burkina Faso to $US 6.91 billion (95% UI: 3.32, 11.4) in Pakistan per five-year birth cohort. Returns in income per child were above the estimated per child cost of providing SQ-LNS. These findings demonstrate that scaling-up SQ-LNS among children aged 6-24 months may lead to substantial human capital gains in countries with a high-burden of child undernutrition. Longitudinal studies on the long-term effects of SQ-LNS are needed to refine model parameters and to better characterize the impacts on broader health and human capital outcomes.
- Open Access
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (7) , e0001949
Starting at the community: Treatment-seeking pathways of children with suspected severe malaria in Uganda
Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, p<0.001) and more likely to receive the second or third-line injectable antimalarial (artemether: 22% vs. 2%, p<0.001, quinine: 12% vs. 3%, p<0.001). Children who only went to non-RHF providers were less likely to receive an artemisinin-based combination therapy (ACT) than children who attended a RHF (odds ratio [OR] = 0.64, 95% CI 0.51–0.79, p<0.001). Children who did not go to any provider after seeing a CHW were the least likely to receive an ACT (OR = 0.21, 95% CI 0.14–0.34, p<0.001). Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (7) , e0001949
Open AccessStarting at the community: Treatment-seeking pathways of children with suspected severe malaria in Uganda
Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, p<0.001) and more likely to receive the second or third-line injectable antimalarial (artemether: 22% vs. 2%, p<0.001, quinine: 12% vs. 3%, p<0.001). Children who only went to non-RHF providers were less likely to receive an artemisinin-based combination therapy (ACT) than children who attended a RHF (odds ratio [OR] = 0.64, 95% CI 0.51–0.79, p<0.001). Children who did not go to any provider after seeing a CHW were the least likely to receive an ACT (OR = 0.21, 95% CI 0.14–0.34, p<0.001). Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.
- Open Access
- 21 February 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (2) , e1004189
Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate in the Democratic Republic of the Congo, Nigeria, and Uganda: An operational study
Background: For a full treatment course of severe malaria, community-administered pre-referral rectal artesunate (RAS) should be completed by post-referral treatment consisting of an injectable antimalarial and oral artemisinin-based combination therapy (ACT). This study aimed to assess compliance with this treatment recommendation in children under 5 years. Methods and findings: This observational study accompanied the implementation of RAS in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda between 2018 and 2020. Antimalarial treatment was assessed during admission in included referral health facilities (RHFs) in children under 5 with a diagnosis of severe malaria. Children were either referred from a community-based provider or directly attending the RHF. RHF data of 7,983 children was analysed for appropriateness of antimalarials; a subsample of 3,449 children was assessed additionally for dosage and method of ACT provision (treatment compliance). A parenteral antimalarial and an ACT were administered to 2.7% (28/1,051) of admitted children in Nigeria, 44.5% (1,211/2,724) in Uganda, and 50.3% (2,117/4,208) in DRC. Children receiving RAS from a community-based provider were more likely to be administered post-referral medication according to the guidelines in DRC (adjusted odds ratio (aOR) = 2.13, 95% CI 1.55 to 2.92, P < 0.001), but less likely in Uganda (aOR = 0.37, 95% CI 0.14 to 0.96, P = 0.04) adjusting for patient, provider, caregiver, and other contextual factors. While in DRC, inpatient ACT administration was common, ACTs were often prescribed at discharge in Nigeria (54.4%, 229/421) and Uganda (53.0%, 715/1,349). Study limitations include the unfeasibility to independently confirm the diagnosis of severe malaria due to the observational nature of the study. Conclusions: Directly observed treatment was often incomplete, bearing a high risk for partial parasite clearance and disease recrudescence. Parenteral artesunate not followed up with oral ACT constitutes an artemisinin monotherapy and may favour the selection of resistant parasites. In connection with the finding that pre-referral RAS had no beneficial effect on child survival in the 3 study countries, concerns about an effective continuum of care for children with severe malaria seem justified. Stricter compliance with the WHO severe malaria treatment guidelines is critical to effectively manage this disease and further reduce child mortality. Trial registration: ClinicalTrials.gov (NCT03568344).
- 21 February 2023
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 20 (2) , e1004189
Open AccessHealth worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate in the Democratic Republic of the Congo, Nigeria, and Uganda: An operational study
Background: For a full treatment course of severe malaria, community-administered pre-referral rectal artesunate (RAS) should be completed by post-referral treatment consisting of an injectable antimalarial and oral artemisinin-based combination therapy (ACT). This study aimed to assess compliance with this treatment recommendation in children under 5 years. Methods and findings: This observational study accompanied the implementation of RAS in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda between 2018 and 2020. Antimalarial treatment was assessed during admission in included referral health facilities (RHFs) in children under 5 with a diagnosis of severe malaria. Children were either referred from a community-based provider or directly attending the RHF. RHF data of 7,983 children was analysed for appropriateness of antimalarials; a subsample of 3,449 children was assessed additionally for dosage and method of ACT provision (treatment compliance). A parenteral antimalarial and an ACT were administered to 2.7% (28/1,051) of admitted children in Nigeria, 44.5% (1,211/2,724) in Uganda, and 50.3% (2,117/4,208) in DRC. Children receiving RAS from a community-based provider were more likely to be administered post-referral medication according to the guidelines in DRC (adjusted odds ratio (aOR) = 2.13, 95% CI 1.55 to 2.92, P < 0.001), but less likely in Uganda (aOR = 0.37, 95% CI 0.14 to 0.96, P = 0.04) adjusting for patient, provider, caregiver, and other contextual factors. While in DRC, inpatient ACT administration was common, ACTs were often prescribed at discharge in Nigeria (54.4%, 229/421) and Uganda (53.0%, 715/1,349). Study limitations include the unfeasibility to independently confirm the diagnosis of severe malaria due to the observational nature of the study. Conclusions: Directly observed treatment was often incomplete, bearing a high risk for partial parasite clearance and disease recrudescence. Parenteral artesunate not followed up with oral ACT constitutes an artemisinin monotherapy and may favour the selection of resistant parasites. In connection with the finding that pre-referral RAS had no beneficial effect on child survival in the 3 study countries, concerns about an effective continuum of care for children with severe malaria seem justified. Stricter compliance with the WHO severe malaria treatment guidelines is critical to effectively manage this disease and further reduce child mortality. Trial registration: ClinicalTrials.gov (NCT03568344).
- Open Access
- 21 December 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (2) , e256-e264
Health system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints
- 21 December 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (2) , e256-e264
Open AccessHealth system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints
- Open Access
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (9) , e0000464
Community access to rectal artesunate for malaria (CARAMAL): A large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda
The key to reducing malaria deaths in highly endemic areas is prompt access to quality case management. Given that many severe cases occur at peripheral level, rectal artesunate (RAS) in the form of suppositories was developed in the 1990s, allowing for rapid initiation of life-saving antimalarial treatment before referral to a health facility with full case management capabilities. One randomized controlled trial published in 2009 showed a protective effect of RAS pre-referral treatment against overall mortality of 26%, but with significant differences according to study sites and length of referral. Two important issues remained unaddressed: (1) whether the mortality impact of RAS observed under controlled trial conditions could be replicated under real-world circumstances; and (2) clear operational guidance for the wide-scale implementation of RAS, including essential health system determinants for optimal impact. From 2018 to 2020, the Community Access to Rectal Artesunate for Malaria (CARAMAL) project was conducted as a large-scale observational implementation study in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda (registered on ClinicalTrials.gov as NCT03568344). CARAMAL aimed to provide high-quality field evidence on the two issues above, in three remote settings with high malaria endemicity. A number of complementary study components were implemented. The core of the CARAMAL study was the Patient Surveillance System (PSS), which allowed tracking of cases of severe febrile illness from first contact at the periphery to a referral health facility, and then on to a Day 28 visit at the home of the patient. Community and provider cross-sectional surveys complemented the PSS. Here we describe in some detail RAS implementation, as well as the key CARAMAL study components and basic implementation experience. This manuscript does not intend to present key study results, but provides an extensive reference document for the companion papers describing the impact, referral process, post-referral treatment and costing of the RAS intervention.
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (9) , e0000464
Open AccessCommunity access to rectal artesunate for malaria (CARAMAL): A large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda
The key to reducing malaria deaths in highly endemic areas is prompt access to quality case management. Given that many severe cases occur at peripheral level, rectal artesunate (RAS) in the form of suppositories was developed in the 1990s, allowing for rapid initiation of life-saving antimalarial treatment before referral to a health facility with full case management capabilities. One randomized controlled trial published in 2009 showed a protective effect of RAS pre-referral treatment against overall mortality of 26%, but with significant differences according to study sites and length of referral. Two important issues remained unaddressed: (1) whether the mortality impact of RAS observed under controlled trial conditions could be replicated under real-world circumstances; and (2) clear operational guidance for the wide-scale implementation of RAS, including essential health system determinants for optimal impact. From 2018 to 2020, the Community Access to Rectal Artesunate for Malaria (CARAMAL) project was conducted as a large-scale observational implementation study in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda (registered on ClinicalTrials.gov as NCT03568344). CARAMAL aimed to provide high-quality field evidence on the two issues above, in three remote settings with high malaria endemicity. A number of complementary study components were implemented. The core of the CARAMAL study was the Patient Surveillance System (PSS), which allowed tracking of cases of severe febrile illness from first contact at the periphery to a referral health facility, and then on to a Day 28 visit at the home of the patient. Community and provider cross-sectional surveys complemented the PSS. Here we describe in some detail RAS implementation, as well as the key CARAMAL study components and basic implementation experience. This manuscript does not intend to present key study results, but provides an extensive reference document for the companion papers describing the impact, referral process, post-referral treatment and costing of the RAS intervention.
- Open Access
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (6) , e0000218
Large gains in schooling and income are possible from minimizing adverse birth outcomes in 121 low- and middle-income countries: A modelling study
While the global contributions of adverse birth outcomes to child morbidity and mortality is relatively well documented, the potential long-term schooling and economic consequences of adverse birth outcomes has not been estimated. We sought to quantify the potential schooling and lifetime income gains associated with reducing the excess prevalence of adverse birth outcomes in 121 low- and middle-income countries. We used a linear deterministic model to estimate the potential gains in schooling and lifetime income that may be achieved by attaining theoretical minimum prevalence of low birthweight, preterm birth and small-for-gestational age births at the national, regional, and global levels. We estimated that potential total gains across the 121 countries from reducing low birthweight to the theoretical minimum were 20.3 million school years (95% CI: 6.0,34.8) and US$ 68.8 billion (95% CI: 20.3,117.9) in lifetime income gains per birth cohort. As for preterm birth, we estimated gains of 9.8 million school years (95% CI: 1.5,18.4) and US$ 41.9 billion (95% CI: 6.1,80.9) in lifetime income. The potential gains from small-for-gestational age were 39.5 million (95% CI: 19.1,60.3) school years and US$113.6 billion (95% CI: 55.5,174.2) in lifetime income gained. In summary, reducing the excess prevalence of low birthweight, preterm birth or small-for-gestational age births in low- and middle-income countries may lead to substantial long-term human capital gains in addition to benefits on child mortality, growth, and development as well as on risk of non-communicable diseases in adults and other consequences across the life course.
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (6) , e0000218
Open AccessLarge gains in schooling and income are possible from minimizing adverse birth outcomes in 121 low- and middle-income countries: A modelling study
While the global contributions of adverse birth outcomes to child morbidity and mortality is relatively well documented, the potential long-term schooling and economic consequences of adverse birth outcomes has not been estimated. We sought to quantify the potential schooling and lifetime income gains associated with reducing the excess prevalence of adverse birth outcomes in 121 low- and middle-income countries. We used a linear deterministic model to estimate the potential gains in schooling and lifetime income that may be achieved by attaining theoretical minimum prevalence of low birthweight, preterm birth and small-for-gestational age births at the national, regional, and global levels. We estimated that potential total gains across the 121 countries from reducing low birthweight to the theoretical minimum were 20.3 million school years (95% CI: 6.0,34.8) and US$ 68.8 billion (95% CI: 20.3,117.9) in lifetime income gains per birth cohort. As for preterm birth, we estimated gains of 9.8 million school years (95% CI: 1.5,18.4) and US$ 41.9 billion (95% CI: 6.1,80.9) in lifetime income. The potential gains from small-for-gestational age were 39.5 million (95% CI: 19.1,60.3) school years and US$113.6 billion (95% CI: 55.5,174.2) in lifetime income gained. In summary, reducing the excess prevalence of low birthweight, preterm birth or small-for-gestational age births in low- and middle-income countries may lead to substantial long-term human capital gains in addition to benefits on child mortality, growth, and development as well as on risk of non-communicable diseases in adults and other consequences across the life course.
- Open Access
Real world costs and barriers to the successful implementation of rectal artesunate as pre-referral treatment for severe malaria in Sub-Saharan Africa
Background: Rectal artesunate (RAS), an efficacious pre-referral treatment for severe malaria in children, was deployed at scale in Uganda, Nigeria and DR Congo. In addition to distributing RAS, implementation required additional investments in crucial but neglected components in the care for severe malaria. We examined the real-world costs and barriers to RAS implementation. Methods: We collected primary data on baseline health system gaps and subsequent RAS implementation expenditures. We calculated the equivalent annual cost of RAS implementation per child under 5 at risk of severe malaria, from a health system perspective, separating neglected routine health system components from incremental RAS introduction costs. Findings: The largest baseline gaps were irregular health worker supervisions, inadequate referral facility worker training, and inadequate malaria commodity supplies. Health worker training and behaviour change campaigns were the largest startup costs, while supervision and supply chain management accounted for most annual routine costs. The equivalent annual costs of preparing the health system for treating severe malaria with RAS were $2.31, $2.20 and 4.15 per child at risk in Uganda, Nigeria and DRC. The incremental costs of introducing RAS, net of routine neglected components, accounted for a minority at $0.72, $0.59 and $0.94. Interpretation: While RAS has been touted as a cost-effective pre-referral treatment for severe malaria in children, its real-world potential is limited by weak and under-financed continuums of care. Scaling up RAS or other interventions relying on community healthcare providers only makes sense alongside additional, essential health system investments sustained over the long-term. Funding: Unitaid
Open AccessReal world costs and barriers to the successful implementation of rectal artesunate as pre-referral treatment for severe malaria in Sub-Saharan Africa
Background: Rectal artesunate (RAS), an efficacious pre-referral treatment for severe malaria in children, was deployed at scale in Uganda, Nigeria and DR Congo. In addition to distributing RAS, implementation required additional investments in crucial but neglected components in the care for severe malaria. We examined the real-world costs and barriers to RAS implementation. Methods: We collected primary data on baseline health system gaps and subsequent RAS implementation expenditures. We calculated the equivalent annual cost of RAS implementation per child under 5 at risk of severe malaria, from a health system perspective, separating neglected routine health system components from incremental RAS introduction costs. Findings: The largest baseline gaps were irregular health worker supervisions, inadequate referral facility worker training, and inadequate malaria commodity supplies. Health worker training and behaviour change campaigns were the largest startup costs, while supervision and supply chain management accounted for most annual routine costs. The equivalent annual costs of preparing the health system for treating severe malaria with RAS were $2.31, $2.20 and 4.15 per child at risk in Uganda, Nigeria and DRC. The incremental costs of introducing RAS, net of routine neglected components, accounted for a minority at $0.72, $0.59 and $0.94. Interpretation: While RAS has been touted as a cost-effective pre-referral treatment for severe malaria in children, its real-world potential is limited by weak and under-financed continuums of care. Scaling up RAS or other interventions relying on community healthcare providers only makes sense alongside additional, essential health system investments sustained over the long-term. Funding: Unitaid
- Open Access
Starting at the community: Treatment seeking pathways of children with suspected severe malaria in Uganda
Introduction Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. Methods An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Results Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, pConclusions Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.
Open AccessStarting at the community: Treatment seeking pathways of children with suspected severe malaria in Uganda
Introduction Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. Methods An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Results Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, pConclusions Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.